Physician profile
Brian H Kim
NPI 1053568873
$5,998.65
in general payments reported to CMS, 2019-2025
54 companies · $1,154 in 2025
The $1,154 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $342 · 2020: $124 · 2021: $699 · 2022: $1,276 · 2023: $945 · 2024: $1,460 · 2025: $1,154.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,429 · Education: $130.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,428.83 |
| Education | $129.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $997.90 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $630.36 | 2019-2025 | Lynparza, Tagrisso, Calquence |
| Medical Device Business Services, INC. | $427.44 | 2022 | |
| Janssen Biotech, INC. | $421.03 | 2021-2025 | Erleada, Rybrevant, Akeega |
| Bayer Healthcare Pharmaceuticals INC. | $397.78 | 2022-2025 | |
| Merck Sharp & Dohme LLC | $310.12 | 2019-2025 | Keytruda, Keytruda Qlex, Welireg |
| Pfizer INC. | $267.44 | 2020-2025 | |
| Incyte Corporation | $267.38 | 2019-2025 | Jakafi |
| Abbvie INC. | $179.20 | 2021-2025 | |
| Seagen INC. | $141.94 | 2021-2023 | Adcetris |
| Astellas Pharma US INC | $140.98 | 2019 | |
| Aveo Pharmaceuticals, INC. | $126.18 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $107.54 | 2020-2025 | Reblozyl, Opdivo |
| Lilly USA, LLC | $101.77 | 2022-2025 | Verzenio, Jaypirca, Retevmo |
| Daiichi Sankyo INC. | $101.73 | 2021-2025 | Datroway |
Show all 54 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $99.99 | 2022 | |
| Amgen INC. | $79.41 | 2019-2021 | |
| Pharmacyclics LLC, An Abbvie Company | $78.23 | 2021-2023 | Imbruvica |
| Tempus Ai, INC | $77.93 | 2024-2025 | Xt Cdx |
| Genzyme Corporation | $76.95 | 2020-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $74.05 | 2023-2025 | Fruzaqla, Iclusig, Vpriv |
| Sumitomo Pharma America, INC. | $69.69 | 2023-2025 | Orgovyx |
| Alexion Pharmaceuticals, INC. | $63.77 | 2019-2024 | Ultomiris |
| Celgene Corporation | $59.05 | 2019-2023 | Reblozyl |
| Novocure INC. | $51.85 | 2021-2024 | Optune |
| Myriad Genetic Laboratories, INC. | $48.34 | 2023 | Precisetumor |
| Emd Serono, INC. | $44.77 | 2021-2025 | |
| Genentech USA, INC. | $38.64 | 2024-2025 | Venclexta |
| Novo Nordisk INC | $37.54 | 2023-2025 | Rebinyn, Saxenda, Wegovy |
| Baxter Healthcare | $34.34 | 2022 | |
| Eisai INC. | $31.98 | 2019-2024 | |
| Pulmonx Corporation | $30.49 | 2024 | Pulmonx Chartis Tablet Console, Chartis Catheter, Zephyr Endobronchial Valve |
| Beone Medicines USA, INC. | $25.95 | 2025 | Brukinsa |
| Myovant Sciences INC. | $25.94 | 2021-2022 | |
| Pharmaessentia USA Corporation | $25.33 | 2025 | Besremi |
| Kite Pharma, INC. | $24.52 | 2020 | |
| Adaptive Biotechnologies Corporation | $21.61 | 2023 | Clonoseq |
| Pharmacosmos Therapeutics INC. | $19.08 | 2022 | |
| Jazz Pharmaceuticals INC. | $18.66 | 2025 | |
| Geron Corporation | $16.98 | 2025 | Rytelo |
| Aadi Bioscience, INC. | $16.81 | 2024 | Fyarro |
| Legend Biotech USA INC. | $16.65 | 2024 | |
| Stemline Therapeutics INC. | $16.39 | 2025 | Orserdu |
| Array Biopharma INC | $16.33 | 2025 | Tukysa, Braftovi, Mektovi |
| Rigel Pharmaceuticals, INC. | $15.84 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $14.83 | 2023 | Libtayo |
| Acrotech Biopharma INC. | $14.68 | 2021 | |
| Immunogen, INC. | $14.41 | 2023 | Elahere |
| Alfasigma USA, INC. | $14.36 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $14.36 | 2020 | |
| Amag Pharmaceuticals, INC. | $13.96 | 2022 | |
| Sun Pharmaceutical Industries INC. | $13.18 | 2022 | |
| Gilead Sciences, INC. | $11.92 | 2021 | |
| Shire North American Group INC | $11.05 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Kim listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.